Literature DB >> 10605708

Activation of the plasma kallikrein/kinin system on cells: a revised hypothesis.

A H Schmaier1, R Røjkjaer, Z Shariat-Madar.   

Abstract

Mesh:

Substances:

Year:  1999        PMID: 10605708

Source DB:  PubMed          Journal:  Thromb Haemost        ISSN: 0340-6245            Impact factor:   5.249


× No keyword cloud information.
  7 in total

1.  Endothelial AT(2)-receptors: chicken or egg?

Authors:  Paul M Vanhoutte
Journal:  Br J Pharmacol       Date:  2002-06       Impact factor: 8.739

Review 2.  Complement, Kinins, and Hereditary Angioedema: Mechanisms of Plasma Instability when C1 Inhibitor is Absent.

Authors:  Allen P Kaplan; Kusumam Joseph
Journal:  Clin Rev Allergy Immunol       Date:  2016-10       Impact factor: 8.667

3.  Kallikrein activates bradykinin B2 receptors in absence of kininogen.

Authors:  Dauren Biyashev; Fulong Tan; Zhenlong Chen; Kai Zhang; Peter A Deddish; Ervin G Erdös; Claudie Hecquet
Journal:  Am J Physiol Heart Circ Physiol       Date:  2005-11-04       Impact factor: 4.733

Review 4.  The many faces of the contact pathway and their role in thrombosis.

Authors:  Rebecca S Woodruff; Bruce Sullenger; Richard C Becker
Journal:  J Thromb Thrombolysis       Date:  2011-07       Impact factor: 2.300

5.  Active plasma kallikrein localizes to mast cells and regulates epithelial cell apoptosis, adipocyte differentiation, and stromal remodeling during mammary gland involution.

Authors:  Jennifer N Lilla; Ravi V Joshi; Charles S Craik; Zena Werb
Journal:  J Biol Chem       Date:  2009-03-18       Impact factor: 5.157

6.  AT(2) receptor-dependent vasodilation is mediated by activation of vascular kinin generation under flow conditions.

Authors:  Jun Katada; Masataka Majima
Journal:  Br J Pharmacol       Date:  2002-06       Impact factor: 8.739

7.  Genome-wide protein QTL mapping identifies human plasma kallikrein as a post-translational regulator of serum uPAR levels.

Authors:  Michael A Portelli; Mateusz Siedlinski; Ceri E Stewart; Dirkje S Postma; Maartje A Nieuwenhuis; Judith M Vonk; Peter Nurnberg; Janine Altmuller; Miriam F Moffatt; Andrew J Wardlaw; Stuart G Parker; Martin J Connolly; Gerard H Koppelman; Ian Sayers
Journal:  FASEB J       Date:  2013-11-18       Impact factor: 5.191

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.